Repligen's Q4 Earnings Beat Estimates, Revenues In Line

Repligen Corporation RGEN reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of 48 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues were $168 million, up 0.6% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 3% organically. The reported figure was in line with the Zacks Consensus Estimate.In the past year, shares of Repligen have lost 15.9% compared with the industry’s decline of 8.4%.Image Source: Zacks Investment ResearchMore on RGEN's Q4 EarningsProduct revenues (including revenues from base business) were $167.4 million, up 0.7% from the year-ago level. Royalty and other revenues amounted to $0.15 million, down almost 44.4% year over year.The company’s base business can be categorized under four franchises — filtration, chromatography, protein and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues, which were nil during the fourth quarter. Hence, revenues from the base business were equivalent to total revenues.While CDMO sales rose around 40% year over year, revenues from the company’s equipment business rose about 20%. Per management, CDMO and equipment sales also rose on a sequential basis.RGEN's Costs, Margins & Cash PositionAdjusted gross margin was 50.7%, lower than 52.5% in the year-ago period.Adjusted research and development expenses totaled approximately $11.4 million, up 11.7% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 2.1% to $48.5 million.Adjusted operating income totaled $25 million compared with $30 million in the year-ago period.Adjusted operating margin was 14.9% in the fourth quarter compared with 17.8% in the year-ago quarter.As of Dec. 31, 2024, Repligen had cash and cash equivalents worth $757 million compared with $784 million as of Sept. 30, 2024.RGEN's Full-Year ResultsIn 2024, Repligen generated revenues of $634.4 million, which reflected around 0.3% growth year over year.For the same period, the company reported adjusted earnings of $1.58 per share, down from adjusted earnings of $1.65 per share in the year-ago period.RGEN's 2025 GuidanceThe company expects total revenues to be in the range of $685-$710 million in 2025.Adjusted EPS is anticipated to be between $1.67 and $1.76.Repligen expects an adjusted gross margin between 51% and 52% for 2025.Adjusted operating income is expected in the range of $99-$106 million.Repligen Corporation Price, Consensus and EPS Surprise Repligen Corporation price-consensus-eps-surprise-chart | Repligen Corporation QuoteRGEN's Zacks Rank & Stocks to ConsiderRepligen currently carries a Zacks Rank #3 (Hold).Some top-ranked stocks in the biotech sector are argenx SE ARGX and Pacira BioSciences, Inc. PCRX, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.In the past 60 days, estimates for argenx’s earnings per share have increased from $9.07 to $10.85 for 2025. In the past year, shares of ARGX have risen 59.5%.ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.46 for 2025. In the past year, shares of PCRX have decreased 14.2%.PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Repligen Corporation (RGEN): Free Stock Analysis Report Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report argenex SE (ARGX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks